For Which Cancer Types can Neuron-Specific Enolase be Clinically Helpful in Turkish Patients? |
Bilgin, Elif
(Basic Oncology, Istanbul University Oncology Institute)
Dizdar, Yavuz (Clinical Oncology, Istanbul University Oncology Institute) Serilmez, Murat (Basic Oncology, Istanbul University Oncology Institute) Soydinc, Hilal Oguz (Basic Oncology, Istanbul University Oncology Institute) Yasasever, Ceren Tilgen (Basic Oncology, Istanbul University Oncology Institute) Duranyildiz, Derya (Basic Oncology, Istanbul University Oncology Institute) Yasasever, Vildan (Basic Oncology, Istanbul University Oncology Institute) |
1 | Li X, Asmitananda T, Gao L, et al (2012). Biomarkers in the lung cancer diagnosis: a clinical perspective. Neoplasma, 59, 500-7. DOI ScienceOn |
2 | Lilleby W, Paus E, Skovlund E, Fossa SD (2001). Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer. Prostate, 46, 126-33. DOI |
3 | Massarelli G, Onida GA, Piras MA, et al (1999). Neuron-specific enolase (gamma enolase, gamma-gamma dimer) expression in Hodgkin's disease and large cell lymphomas. Anticancer Res, 19, 3933-8. |
4 | Nakatsuka S, Nishiu M, Tomita Y, et al (2002). Enhanced expression of neuron-specific enolase (NSE) in pyothoraxassociated lymphoma (PAL). Jpn J Cancer Res, 93, 411-6. DOI |
5 | Pejcic I, Vrbic S, Filipovic S, et al (2010). Significance of serum tumor markers monitoring metastases in carcinomas of unknown primary site. Vojnosanit Pregl, 67, 723-31. DOI |
6 | Peshavaria M, Day INM (1991). Molecular structure of the human muscle-specific enolase gene (EN03). Biochem J, 275, 427-33. |
7 | Ramage JK, Davies AH, Ardill J, et al (2005). Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut, 4, 1-16. |
8 | Schmidt D, Harms D, Burdach S (1985). Malignant peripheral neuroectodermal tumours of childhood and adolescence. Virchows Arch A Pathol Anat Histopathol, 406, 351-65. DOI |
9 | Song TJ, Choi YC, Lee KY, Kim WJ (2012). Serum and cerebrospinal fluid neuron-specific enolase for diagnosis of tuberculous meningitis. Yonsei Med J, 53, 1068-72. DOI ScienceOn |
10 | Sung HJ, Cho JY (2008). Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep, 41, 615-25. DOI ScienceOn |
11 | Wojcik E, Jakubowicz J, Skotnicki P, Sas-Korczynska B, Kulpa JK (2010). IL-6 and VEGF in small cell lung cancer patients. Anticancer Res, 30, 1773-8. |
12 | Xue F, Wang L, Zhang M, Cai L (2011). Clinical significance of detection of serum values of neuron specific enolase before and after treatment for small cell lung cancer. Zhongguo Fei Ai Za Zhi, 14, 723-6. |
13 | Yasasever V, Meral R, Camlica H, Duranyildiz D, Dalay N (1999). Serum NSE levels in the Turkish population. J Tumor Marker Oncology, 14, 35-40. |
14 | Zhao X, Wang M (2011). Clinical utility of serum tumor markers in lung cancer. Zhongguo Fei Ai Za Zhi, 14, 286-91. |
15 | Bossuyt PM, Reitsma JB, Bruns DE, et al (2004). Towards complete and Accurate reporting of studies of diagnostic accuracy: the STARD initiative. Fam Pract, 21, 4-10. DOI ScienceOn |
16 | Humez S, Monet M, Legrand G, et al (2006). Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells. Endocr Relat Cancer, 13, 181-95. DOI ScienceOn |
17 | Emin EA, Gunduz A, Batum O, et al (2010). Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study. Arch Bronconeumol, 46, 364-9. |
18 | Fizazi K, Cojean I, Pignon JP, et al (1998). Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer, 82, 1049-55. DOI |
19 | Greenberg AK, Lee MS (2007). Biomarkers for lung cancer: clinical uses. Curr Opin Pulm Med, 13, 249-55. DOI ScienceOn |
20 | Hvamstad T, Jordal A, Hekmat N, Paus E, Fossa SD (2003). Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol, 44, 215-21. DOI ScienceOn |
21 | Kamiya N, Akakura K, Suzuki H, et al (2003). Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol, 44, 309-14. DOI ScienceOn |
22 | Kodet R, Kodetova D, Smelhaus V (1991). Tumors of the peripheral sympathetic nervous system in childhood. Immunohistochemical study. Cesk Patol, 27, 97-104. |
23 | Ather MH, Abbas F, Faruqui N, Israr M, Pervez S (2008). Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol, 8, 21. DOI ScienceOn |
24 | Berruti A, Dogliotti L, Mosca A, et al (2000). Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer, 88, 2590-7. DOI |